Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development
Executive Summary
US agency’s list of off-patent, off-exclusivity drugs that lack generic versions is aimed at improving transparency and encouraging competition, but almost half the 267 listed products involve complex issues that would require further decision-making by FDA ahead of ANDA submission.
You may also be interested in...
US FDA’s First Competitive Generic Therapy Approval Comes With A Twist
Apotex’s potassium chloride oral solution is eligible for 180-day exclusivity under new expedited pathway even though Amneal’s generic referencing same product was approved three weeks earlier; Amneal's continued marketing will not be blocked by Apotex’s exclusivity, which is forfeited if it fails to launch within 75 days.
US FDA’s First Competitive Generic Therapy Approval Comes With A Twist
Apotex’s potassium chloride oral solution is eligible for 180-day exclusivity under new expedited pathway even though Amneal’s generic referencing same product was approved three weeks earlier; Amneal's continued marketing will not be blocked by Apotex’s exclusivity, which is forfeited if it fails to launch within 75 days.
US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.